Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$19M Sell
53,912
-2,312
-4% -$824K 0.6% 35
2025
Q4
$18.4M Buy
56,224
+38,554
+218% +$12.2M 0.53% 37
2025
Q3
$4.95M Sell
17,670
-1,688
-9% -$490K 0.15% 88
2025
Q2
$5.41M Buy
19,358
+183
+1% +$51.8K 0.18% 85
2025
Q1
$5.98M Buy
19,175
+286
+2% +$84.5K 0.25% 87
2024
Q4
$4.91M Buy
18,889
+2,122
+13% +$630K 0.03% 86
2024
Q3
$5.4M Sell
16,767
-2,051
-11% -$671K 0.22% 70
2024
Q2
$5.88M Buy
18,818
+2,047
+12% +$601K 0.3% 61
2024
Q1
$4.77M Buy
+16,771
New +$4.91M 0.22% 74

Other funds holding AMGN

BNP Paribas's AMGN Position: Q1 2026 in Review

BNP Paribas reduced its Amgen (AMGN) stake by 4.1% in Q1 2026, selling an estimated $824K and leaving 53,912 shares worth $19M. The position accounts for 0.6% of the portfolio, ranked #35.

BNP Paribas first reported a position in AMGN in Q1 2024 and has held it in 9 quarters since. 3,126 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • BNP Paribas held 53,912 shares of Amgen worth $19M as of Q1 2026.
  • BNP Paribas sold 2,312 Amgen shares in Q1 2026, an estimated $824K.
  • Amgen made up 0.6% of BNP Paribas's portfolio in Q1 2026, its #35 holding.
  • BNP Paribas first reported a position in Amgen in Q1 2024 and has held it in 9 quarters since.
  • 3,126 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on BNP Paribas's 13F filing for Q1 2026, filed 12 May 2026.